Document:

Form of 2010 Common Stock Bridge Warrant

 Exhibit 4.8 

FORM OF COMMON STOCK WARRANT 

THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT THERETO SHALL BE
EFFECTIVE UNDER THE SECURITIES ACT, OR (B) THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT IS AVAILABLE, AND (2) THERE SHALL HAVE BEEN
COMPLIANCE WITH ALL APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS. 
  

			
	 No. CS-[    ]

Issue Date: [            ]
	 	 Warrant to Purchase [            ] Shares

 of Common Stock

WARRANT TO PURCHASE 

COMMON STOCK 
 OF

 BG MEDICINE, INC. 

(A DELAWARE CORPORATION) 

BG Medicine, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that
                                        
 or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company, at any time during the Exercise Period as set forth in Section 1 below, [insert number equal
to (.75)*(original principal amount of the Note) / $6.50] shares of Common Stock, par value $0.001 per share (the “Common Stock”), at a purchase price per share of Common Stock of $0.01 (the “Exercise Price”).
This “Warrant” is issued pursuant to that certain Securities Purchase Agreement dated as of March 30, 2010 between the Company and the Purchasers (as defined therein) (the “Purchase Agreement”), and is entitled to the
benefits of the Purchase Agreement. The terms of all Warrants issued pursuant to the Purchase Agreement (including this Warrant) are and will be identical except as to the name of the holder thereof, the number of shares of Common Stock exercisable
by such holder and the date of issuance thereof. Except as to those terms otherwise defined in this Warrant, all capitalized terms used in this Warrant shall have the respective meanings ascribed to them in the Purchase Agreement. 

1. The Exercise Period. Subject to Section 2.2 and the other terms and conditions of this Warrant, this Warrant is exercisable at any time
(i) on or after the Bridge Expiration Date, provided, however, if the Bridge Expiration Date occurs as a result of a Liquidation Event, then this Warrant shall be exercisable immediately prior to and subject to the consummation of the
Liquidation Event, and (ii) on or before 5:00 p.m., EST, on March 30, 2020 (the “Exercise Period”). 

 2. Termination of Warrant on Subsequent Tranche Default. In the event that, at any time this Warrant
is outstanding, the Company conducts a Subsequent Tranche Closing under the Purchase Agreement and the Holder of this Warrant defaults on its obligation to purchase an amount of additional Notes and Warrants in the Subsequent Tranche Closing at
least equal to (i) the defaulting Holder’s allocation percentage of the Aggregate Bridge Amount, as set forth opposite the name of such Purchaser on Schedule A attached to the Purchase Agreement under the caption “Allocation
Percentage,” multiplied by (ii) the aggregate amount of such Subsequent Tranche, then all of this Holder’s rights with respect to this Warrant shall terminate on the Subsequent Tranche Closing; and whether or not this Warrant has been
surrendered for cancellation, the Company will be forever released from all of its obligations and liabilities under this Warrant, and this Warrant will terminate and become null and void. For purposes of determining the number of Notes and Warrants
purchased by a Holder at a Subsequent Tranche Closing, all Notes and Warrants purchased by Affiliates of such Holder at the Subsequent Tranche Closing shall be aggregated with the Notes and Warrants purchased by such Holder (provided that no
securities shall be attributed to more than one entity or person within any such group of affiliated entities or persons). For the avoidance of doubt, Holders may allocate and transfer their Notes and Warrants among their Affiliates, in their sole
discretion, and all Notes and Warrants being purchased by a Holder’s Affiliates shall be attributed to such Holder or group of such Holder’s Affiliates, as applicable, for purposes of determining such Holder’s or such Holder’s
Affiliates’ commitment to purchase its Allocation Percentage of the Aggregate Bridge Amount. 
 3. Exercise. 

3.1 Manner of Exercise; Payment in Cash. This Warrant may be exercised by the Holder, in whole or in part, by
surrendering this Warrant, with the purchase form appended hereto as Exhibit A duly executed by the Holder, at the principal office of the Company, or at such other place as the Company may designate, accompanied by payment in full of the
Exercise Price payable in respect of the number of shares of Common Stock purchased upon such exercise. Payment of the Exercise Price shall be in cash or by certified or official bank check payable to the order of the Company. 

3.2 Effectiveness. Each exercise of this Warrant shall be deemed to have been effected immediately prior to the
close of business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 3.1 above. At such time, the person or persons in whose name or names any certificates for Common Stock (or other securities to
be issued hereunder) shall be issuable upon such exercise as provided in Section 3.3 below shall be deemed to have become the holder or holders of record of the Common Stock represented by such certificates. 

3.3. Delivery of Certificates. As soon as practicable after the exercise of this Warrant in full or in part, and in
any event within ten (10) business days thereafter, the Company at its sole expense will cause to be issued in the name of, and delivered to, the Holder, or, subject to the terms and conditions hereof, as such Holder may direct: 

(a) A certificate or certificates for the number of full shares of Common Stock to which such Holder shall be entitled
upon such exercise plus, in lieu of any fractional share to which such Holder would otherwise be entitled, cash in an amount determined pursuant to Section 3.4 hereof, and 

 

 2 

 (b) In case such exercise is in part only, a new warrant or warrants (dated
the date hereof) of like tenor, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock (without giving effect to any adjustment therein) equal to the number of such shares called for on the face of this
Warrant minus the number of such shares purchased by the Holder upon such exercise as provided in Section 3.1 above. 

3.4. Fractional Shares. The Company shall not be required upon the exercise of this Warrant to issue any fractional
shares, but shall make an adjustment therefor in cash on the basis of the fair market value of the Common Stock determined pursuant to Section 3.5(c) herein. 

3.5 Right to Convert Warrant into Stock: Net Issuance. 

(a) Right to Convert. In addition to and without limiting the rights of the Holder under the terms of this Warrant,
the Holder shall have the right to convert this Warrant or any portion thereof (the “Conversion Right”) into shares of Common Stock as provided in this Section 3.5. Upon exercise of the Conversion Right with respect to a
particular number of shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall deliver to the Holder (without payment by the Holder of any Exercise Price or any cash or other consideration) that number of
shares of fully paid and nonassessable Common Stock equal to the quotient obtained by dividing (X) the value of this Warrant (or the specified portion hereof) on the Conversion Date (as defined in subsection (b) hereof), which value shall
be determined by subtracting (A) the aggregate Exercise Price of the Converted Warrant Shares immediately prior to the exercise of the Conversion Right from (B) the aggregate fair market value of the Converted Warrant Shares issuable upon
exercise of this Warrant (or the specified portion hereof) on the Conversion Date by (Y) the fair market value of one share of Common Stock on the Conversion Date. 

Expressed as a formula, such conversion shall be computed as follows: 
  

							
	N	  	=	  	B-A	  	
		  		  	 	  	
		  		  	Y	  	

							
				
	where:	  	N	  	=	  	the number of shares of Common Stock that may be issued to Holder
				
		  	Y	  	=	  	the fair market value (FMV) of one share of Common Stock
				
		  	A	  	=	  	the aggregate Warrant Price (Converted Warrant Shares x Exercise Price)
				
		  	B	  	=	  	the aggregate FMV (i.e., FMV x Converted Warrant Shares)

  

 3 

 No fractional shares shall be issuable upon exercise of the Conversion
Right, and, if the number of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the Holder an amount in cash equal to the fair market value of the resulting fractional share
of the Conversion Date. 
 (b) Method of Exercise. The Conversion Right may be exercised by the Holder by
the surrender of this Warrant at the principal office of the Company together with the Subscription Form in the form attached hereto duly completed and executed and indicating the number of shares subject to this Warrant which are being surrendered
(referred to in Section 3.5(a) hereof as the Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid written statement, or on such
later date as is specified therein (the “Conversion Date”), and, at the election of the Holder hereof, may be made contingent upon the occurrence of any of the events specified in Section 4. Certificates for the shares issuable
upon exercise of the Conversion Right and, if applicable, a new Warrant evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Conversion Date and shall be delivered to the Holder within thirty
(30) days following the Conversion Date. 
 (c) Determination of Fair Market Value. For purposes of
this Section 3.5, “fair market value” of a share of Common Stock as of a particular date (the “Determination Date”) shall mean: 

(i) If the Conversion Right is exercised in connection with and contingent upon a public offering, and if the
Company’s Registration Statement relating to such public offering (“Registration Statement”) has been declared effective by the Securities and Exchange Commission, then the initial “Price to Public” specified in the
final prospectus with respect to such offering. 
 (ii) If the Conversion Right is not exercised in connection
with and contingent upon a public offering, then as follows: 
  

	 	(1)	If traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be the average of the closing prices of the Common Stock on such
exchange over the five-day period ending one Business Day prior to the Determination Date or, if less, such number of days as the Common Stock has been traded on such exchange; 

 

	 	(2)	If traded over-the-counter, the fair market value of the Common Stock shall be deemed to be the average of the closing bid prices of the Common Stock over the five-day
period ending one Business Day prior to the Determination Date or, if less, such number of days as the Common Stock has been traded over-the-counter; and 

  

 4 

	 	(3)	If there is no public market for the Common Stock, then fair market value shall be determined in good faith by the Board of Directors of the Company, including the
Requisite Directors. 

 4. Certain Adjustments. 

4.1 Changes in Common Stock. If the Company shall (i) combine the outstanding shares of Common Stock into a
lesser number of shares, (ii) subdivide the outstanding shares of Common Stock into a greater number of shares, or (iii) issue additional shares of Common Stock as a dividend or other distribution with respect to the Common Stock, the
number of shares of Common Stock to be issued pursuant to the terms of the Warrant shall be equal to the number of shares which the Holder would have been entitled to receive after the happening of any of the events described above if such shares
had been issued immediately prior to the happening of such event, such adjustment to become effective concurrently with the effectiveness of such event. The Exercise Price in effect immediately prior to any such combination of Common Stock shall,
upon the effectiveness of such combination, be proportionately increased. The Exercise Price in effect immediately prior to any such subdivision of Common Stock or at the record date of such dividend shall upon the effectiveness of such subdivision
or immediately after the record date of such dividend be proportionately reduced. 
 4.2 Reorganizations and
Reclassifications. If there shall occur any capital reorganization or reclassification of the Common Stock (other than a change in par value or a subdivision or combination as provided for in Section 4.1), then, as part of any such
reorganization or reclassification, lawful provision shall be made so that the Holder shall have the right thereafter to receive upon the exercise hereof the kind and amount of shares of stock or other securities or property which such Holder would
have been entitled to receive if, immediately prior to any such reorganization or reclassification, such Holder had held the number of shares of Common Stock which were then purchasable upon the exercise of this Warrant. In any such case,
appropriate adjustment (as reasonably determined by the Board of Directors of the Company) shall be made in the application of the provisions set forth herein with respect to the rights and interests thereafter of the Holder such that the provisions
set forth in this Section 4 (including provisions with respect to adjustment of the Exercise Price) shall thereafter be applicable, as nearly as is reasonably practicable, in relation to any shares of stock or other securities or property
thereafter deliverable upon the exercise of this Warrant. 
 4.3 Merger, Consolidation or Sale of Assets.
Subject to the provisions of this Section 4, if there shall be a merger or consolidation of the Company with or into another corporation (other than a merger or reorganization involving only a change in the state of incorporation of the Company
or the acquisition by the Company of other businesses where the Company survives as a going concern), or the sale of all or substantially all of the Company’s capital stock or assets to any other person, then as a part of such transaction,
provision shall be made so that the Holder shall thereafter be entitled to receive the number of shares of stock or other securities or property of the Company, or of the successor corporation resulting from the merger, consolidation or sale, to
which the Holder would 
  

 5 

 
have been entitled if the Holder had exercised its rights pursuant to the Warrant immediately prior thereto. In any such case, appropriate adjustment shall be made in the application of the
provisions of this Section 4 to the end that the provisions of this Section 4 shall be applicable after that event in as nearly equivalent a manner as may be practicable. 

4.4 Statement of Adjustment. Whenever the Exercise Price or the Common Stock to be issued hereunder shall be
adjusted as provided in this Section 4, the Company shall forthwith file with the Secretary of the Company or at such other place as shall be designated by the Company, a statement, signed by its chief financial officer, showing in detail the
facts requiring such adjustment, the Exercise Price in effect before and after such adjustment and the kind and amount of shares of capital stock, securities or other property thereafter to be received upon the exercise of this Warrant. The Company
shall also cause a copy of such statement to be sent in the manner specified in Section 8.04 of the Purchase Agreement to the Holder. Where appropriate, such copy may be given in advance and may be included as part of a notice required to be
mailed under the provisions of Section 4.5. 
 4.5 Notice of Adjustment. In the event the Company
shall propose to take any action of the types described in Sections 4.1, 4.2 or 4.3, the Company shall give notice to the Holder in the manner set forth in Section 8.04 of the Purchase Agreement, which notice shall specify the record date, if
any, with respect to any such action and the date on which such action is to take place. Such notice shall also set forth such facts with respect thereto as shall be reasonably necessary to indicate the effect of such action (to the extent such
effect may be known at the date of such notice) on the Exercise Price and the number, kind or class of shares or other securities or property which shall be deliverable or purchasable upon the occurrence of such action or deliverable upon the
exercise hereof. In the case of any action which would require the fixing of a record date, such notice shall be given at least ten (10) days prior to the date so fixed, and in case of all other actions, such notice shall be given at least
twenty (20) days prior to the taking of such proposed action. 
 4.6 Taxes. The Company shall pay all
documentary, stamp or other transactional taxes, but excluding any income or withholding taxes, attributable to the issuance or delivery of shares of capital stock of the Company upon the exercise or conversion of this Warrant. 

5. Reservation of Stock. The Company will at all times reserve and keep available, solely for issuance and delivery upon the exercise of this
Warrant, such shares of Common Stock and other stock, securities and property, as from time to time shall be issuable upon the exercise of this Warrant. The Company covenants that all shares of Common Stock so issuable will, when issued, be duly and
validly issued and fully paid and nonassessable. 
 6. Replacement of Warrants. Upon receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably required) in an amount reasonably satisfactory to the Company,
or (in the case of mutilation) upon surrender and cancellation of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor. 
  

 6 

 7. Transferability. Subject to compliance with applicable federal and state securities laws, this
Warrant and all rights hereunder are transferable in whole or in part by the Holder to any person or entity upon written notice to the Company; provided, however, a Holder that is partnership, corporation, trust, joint venture, unincorporated
organization or other entity may transfer this Warrant to an Affiliate without the prior written consent of the Company. The transfer shall be recorded on the books of the Company upon the surrender of this Warrant, properly endorsed, to the Company
at its principal offices, and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. In the event of a partial transfer, the Company shall issue to the holders one or more appropriate new warrants.

 8. No Impairment. The Company will not, by amendment of its certificate of incorporation or through any reorganization, transfer of
assets, consolidation, merger, dissolution, or any other similar voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of the Warrant against impairment due to such event. Without limiting the generality of the foregoing, the Company
(a) will not increase the value assigned to any shares of stock receivable on the exercise of the Warrant above the amount payable therefor on such exercise, (b) will take all action that may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable shares of stock, free from all taxes, liens and charges with respect to the issue thereof, on the exercise of all of the Warrants from time to time outstanding, and (c) will not
consolidate with or merge into any other person or permit any such person to consolidate with or merge into the Company (if the Company is not the surviving person), unless such other person shall expressly assume in writing and will be bound by all
the terms of this Warrant. 
 9. Notices. All notices, requests and other communications hereunder shall be made pursuant to the
provisions of Section 8.04 of the Purchase Agreement. 
 10. Waivers and Modifications. Any term or provision of
this Warrant may be amended or modified, and any term or provision hereof may waived (either generally or in a particular instance and either retroactively or prospectively) upon the written consent of the Company and the Purchasers holding Warrants
with at least 66 2/3% of the aggregate shares
issuable under all of the Warrants then outstanding, provided, however, that this Warrant may not be amended or modified and no provision hereof may be waived in a manner different from any other Warrant without the consent of the
Holder hereof. No waivers of any term, condition or provision of this Warrant, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision. 

11. Headings. The headings in this Warrant are for convenience of reference only and shall in no way modify or affect the meaning or construction
of any of the terms or provisions of this Warrant. 
 12. Governing Law. This Warrant will be governed by and construed in accordance
with and governed by the laws of State of Delaware, without giving effect to the conflict of law principles thereof. 
  

 7 

 IN WITNESS WHEREOF, BG Medicine, Inc. caused this Warrant to be duly executed and delivered.

  

			
	BG MEDICINE, INC.
		
	By:	 	  

	Name:	 	Pieter Muntendam, M.D.
	Title:	 	President & Chief Executive Officer
	Address:	 	610 N Lincoln Street
		 	Waltham, MA 02451

  

 8 

 EXHIBIT A 

PURCHASE FORM 
  

	To:	BG MEDICINE, INC. 

 The
undersigned pursuant to the provisions set forth in the attached Warrant (No. CS-            ), hereby irrevocably elects to (check one): 

 

			
	 	  	(A) purchase              shares of the Common Stock, par value $0.001 per share, of BG Medicine,
Inc. (the “Common Stock”), covered by such Warrant and herewith makes payment of $            , representing the full purchase price for such shares at the price per
share provided for in such Warrant; or
		  
		  
		
	 	  	(B) convert              Converted Warrant Shares into that number of shares of fully paid and
nonassessable shares of Common Stock, determined pursuant to the provisions of Section 3.5 of the Warrant.
		  
		  

 The Common Stock for which the Warrant may be exercised or converted shall be
known herein as the “Warrant Stock.” 
 The undersigned is aware that the Warrant Stock has not been and will not be
registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws. The undersigned understands that reliance by the Company on exemptions under the Securities Act is predicated in part upon
the truth and accuracy of the statements of the undersigned in this Purchase Form. 
 The undersigned represents and warrants
that (1) it has been furnished with all information which it deems necessary to evaluate the merits and risks of the purchase of the Warrant Stock, (2) it has had the opportunity to ask questions concerning the Warrant Stock and the
Company and all questions posed have been answered to its satisfaction, (3) it has been given the opportunity to obtain any additional information it deems necessary to verify the accuracy of any information obtained concerning the Warrant
Stock and the Company and (4) it has such knowledge and experience in financial and business matters that it is able to evaluate the merits and risks of purchasing the Warrant Stock and to make an informed investment decision relating thereto.

 The undersigned hereby represents and warrant that it is purchasing the Warrant Stock for its own account for investment and
not with a view to the sale or distribution of all or any part of the Warrant Stock. 
 The undersigned understands that because
the Warrant Stock has not been registered under the Securities Act, it must continue to bear the economic risk of the investment for an 

 
indefinite period of time and the Warrant Stock cannot be sold unless it is subsequently registered under applicable federal and state securities laws or an exemption from such registration is
available. 
 The undersigned agrees that it will in no event sell or distribute or otherwise dispose of all or any part of the
Warrant Stock unless (1) there is an effective registration statement under the Securities Act and applicable state securities laws covering any such transaction involving the Warrant Stock, or (2) the Company receives an opinion
satisfactory to the Company of the undersigned’s legal counsel stating that such transaction is exempt from registration. The undersigned consents to the placing of a legend on its certificate for the Warrant Stock stating that the Warrant
Stock has not been registered and setting forth the restriction on transfer contemplated hereby and to the placing of a stop transfer order on the books of the Company and with any transfer agents against the Warrant Stock until the Warrant Stock
may be legally resold or distributed without restriction. 
 The undersigned has considered the federal and state income tax
implications of the exercise of the Warrant and the purchase and subsequent sale of the Warrant Stock. 
  

			
	  

		
	Dated:	 	 

  

 2 

 Schedule of Warrant Holders 

AGTC Advisors Fund, L.P. 
 Applied Genomic
Technology Capital Fund, L. P. 
 General Electric Pension Trust 

Gilde Europe Food & Agribusiness Fund, B.V. 

Humana Inc. 
 Legg Mason Special Investment
Trust, Inc. 
 NewcoGen—Élan LLC 

NewcoGen—Long Reign Holding LLC 

NewcoGen—PE LLC 
 NewcoGen Equity Investors
LLC 
 NewcoGen Group LLC 
 SMALLCAP
World Fund, Inc. (nominee name: Clipperbay & Co. HG 22) 
 ST NewcoGen LLC 

Stelios Papadopoulos 
  

 3Securities Purchase Agreement

 Exhibit 4.9 

SECURITIES PURCHASE AGREEMENT 

THIS SECURITIES PURCHASE AGREEMENT, (the “Purchase Agreement”) dated as of March 30, 2010 (the
“Effective Date”), is by and among BG Medicine, Inc., a Delaware Corporation (the “Company”), and the persons or entities identified on Schedule A attached hereto (which persons or entities, with any of their
successors or assignees, are hereinafter referred to individually as a “Purchaser” and collectively, the “Purchasers”). 

RECITALS 

A. The Company has requested that the Purchasers purchase promissory notes convertible into shares of New Stock (as defined below), in
the form attached hereto as Exhibit A (each a “Note” and collectively, the “Notes”), and Warrants (as defined below) for the purchase of Common Stock (as defined below) for an aggregate purchase price of
$6,000,000 on the terms and conditions set forth herein. 
 B. The purchase price of each Note shall be the principal amount
thereof set forth opposite each Purchaser’s name on Schedule A attached hereto. 
 C. The Purchasers have agreed to
purchase the Notes and Warrants on the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual
promises and covenants contained in this Purchase Agreement, the parties hereto, intending to be legally bound, agree as follows: 

ARTICLE I DEFINITIONS 

1.01 Defined Terms. 

As used in this Purchase Agreement and to the extent not otherwise defined herein, the following terms shall have the following meanings:

 “Affiliate”: with respect to any Purchaser that is partnership, corporation, trust, joint venture,
unincorporated organization or other entity, any partnership, corporation, trust, joint venture, unincorporated organization or other entity that is an “accredited investor” within the meaning of Rule 501 promulgated under the Securities
Act and directly or indirectly controls, is controlled by or is under common control with such Purchaser, and the term “control” shall mean, with respect to such Purchaser, the possession, direct or indirect, of the power to direct
or cause the direction of the management and policies of such Purchaser, whether through ownership of voting securities, by contract or otherwise, and including, without limitation, any entity of which the holder is a partner or member, any partner,
officer, director, member or employee of such holder and any venture capital fund now or hereafter existing of which the holder is a partner or member which is controlled by or under common control with one or more general partners of such holder or
shares the same management company with such holder. 
 “Capital Stock”: (a) as to any Person that is a
corporation (i) the authorized shares of such Person’s Capital Stock, including all classes of common, preferred, voting and nonvoting Capital Stock of such Person, (ii) any rights, options or warrants to purchase any Capital Stock

 
(including all classes of common, preferred, voting and nonvoting Capital Stock) of such Person and (iii) securities of any type whatsoever that are, or may become, convertible into or
exercisable or exchangeable for, or that carry or may carry rights to subscribe for, any Capital Stock (including all classes of common, preferred, voting and nonvoting Capital Stock) of such Person; and (b) as to any Person that is not a
corporation or an individual (i) the ownership interests in such Person (however evidenced), including, without limitation, the right to share in profits and losses, the right to receive distributions of cash and property, and the right to
receive allocations of items of income, gain, loss, deduction and credit and similar items from such Person, whether or not such interests include voting or similar rights entitling the holder thereof to exercise control over such Person and
(ii) any rights, options, warrants or securities of any type whatsoever that are, or may become, convertible into or exercisable or exchangeable for, or that carry or may carry rights to subscribe for, any such ownership interests in such
Person. 
 “Common Stock”: the Company’s common stock, par value $0.001 per share. 

“Initial Public Offering”: shall mean the closing of the Company’s first firm commitment underwritten public
offering of Common Stock registered under the Securities Act. 
 “IPO Registration Statement”: the
Company’s Registration Statement on Form S-1 (No. 333-164574), as initially filed with the Securities and Exchange Commission on January 29, 2010, as amended on February 12, 2010 and March 12, 2010, and as further amended from
time to time. 
 “Liquidation Event”: the consummation of either (1) the sale or exchange of all or
substantially all of the outstanding shares of the capital stock of the Company (whether in connection with a merger or consolidation of the Company, an offer to purchase such shares directed to all or substantially all of the stockholders of the
Company, or otherwise), or (2) the sale of all or substantially all of the assets of the Company, including, for clarity, any transaction or series of related transactions deemed to be a liquidation, dissolution or winding up of the Company
pursuant to the Company’s Certificate of Incorporation (defined below). 
 “Material Adverse Effect”: a
material adverse effect on (i) the business, operations, property or financial condition of the Company, or (ii) the validity or enforceability of the Purchase Documents or the rights or remedies of the Purchasers hereunder or thereunder.

 “New Stock”: the shares of the Company’s equity securities issued and sold at the closing of the next
Qualified Financing. 
 “New Stock Price”: the price per share of the New Stock, rounded to the nearest whole
cent, provided that if more than one price is paid by investors purchasing shares of New Stock in the Qualified Financing, the New Stock Price shall be lowest price paid by such investors. 

“Person”: an individual, partnership, corporation, business trust, joint stock company, limited liability company,
trust, unincorporated association, joint venture, governmental authority or other entity of whatever nature. 

“Purchase Agreement”: this Securities Purchase Agreement, as the same may be amended, supplemented or otherwise modified
from time to time. 
  

 2 

 “Purchase Documents”: this Purchase Agreement, the Notes and the Warrants.

 “Qualified Financing”: shall mean the closing of a single or a series of related capital raising
transactions in which the Company issues equity securities to persons or entities which are not currently stockholders, officers or directors of the Company or Affiliates of stockholders, officers or directors of the Company, and in which the
aggregate gross proceeds to the Company are at least Ten Million Dollars ($10,000,000), exclusive of the conversion of the Notes, including, without limitation, the Initial Public Offering. 

“Securities Act”: the Securities Act of 1933, as amended. 

“Senior Debt”: means all of the indebtedness, liabilities, and other obligations the Company owes to (1) Silicon
Valley Bank under that certain Loan and Security Agreement, dated as of November 9, 2007, as amended to date and as further amended, restated, modified, extended or replaced from time to time, by and between the Company and Silicon Valley Bank
(the “Loan Agreement”), (2) any other lenders under other loan agreements for other indebtedness, which indebtedness is secured by a security interest in substantially all of the Company’s assets, that the Board of
Directors of the Company authorizes the Company to incur following the Effective Date. 
 “Warrants”: the
Warrants issued pursuant to the terms of this Purchase Agreement which are in substantially the form attached hereto as Exhibit B. 

ARTICLE II PURCHASE OF CONVERTIBLE NOTES AND WARRANTS 

2.01 Purchase and Sale of Notes and Warrants to the Purchasers.

(a) Subject to and upon the terms and conditions set forth in this Purchase Agreement, and in reliance on the representations and
warranties set forth or referred to herein, the Company agrees to issue and sell to each Purchaser, and each Purchaser agrees to purchase from the Company, at each of the Closings referred to in Section 2.02 below, (i) a Note made by the
Company in favor of such Purchaser in the principal amount set forth opposite the name of such Purchaser on Schedule A attached hereto under the caption “Principal Amount of Note,” and (ii) a Warrant to purchase the number of
shares of Common Stock of the Company set forth opposite the name of such Purchaser on Schedule A attached hereto under the caption “Number of Warrant Shares” at an exercise price equal to $0.01 per share. 

(b) The aggregate principal amount of all Notes to be issued and sold by the Company to the Purchasers pursuant to this Section 2.01
shall be up to $6,000,000 (the “Aggregate Bridge Amount”). The purchase price payable by each Purchaser for the Note and Warrant purchased by it pursuant hereto shall be an amount equal to the principal amount of each Note issued.

  

 3 

 2.02 The Closings. 

(a) Closings and Bridge Expiration Date. The closings of the sale and purchase of the Notes and the Warrants under this Purchase
Agreement shall be made pursuant to the First Closing (as defined below) and one or more subsequent closings (each, a “Closing” and the date of a Closing is hereinafter referred to as a “Closing Date”), which
subsequent closings must occur, if at all, on or before the earliest of (i) the closing of the next Qualified Financing, (ii) the occurrence of a Liquidation Event, or (iii) the one year anniversary of the First Closing (the
“Bridge Expiration Date”). At a Closing, subject to the terms and conditions hereof, the Company will deliver to each Purchaser the Notes and Warrants against payment of the purchase price therefor. The parties agree that the
delivery of this Purchase Agreement and any other documents at a Closing may be effected by means of an exchange of facsimile signatures with original copies to follow by mail or courier service. 

(b) First Closing. The first such Closing shall be for an aggregate amount of up to $2,000,000 of Notes and Warrants and is to be
held at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (or remotely via the exchange of documents and signatures) on March 30, 2010 at 10:00 a.m. (the “First
Closing”). 
 (c) Subsequent Tranche Closings. The balance of the Notes and Warrants
represented by the Aggregate Bridge Amount remaining after the First Closing may be issued and sold by the Company to the Purchasers in up to two subsequent tranches (each, a “Subsequent Tranche”), each in an amount of up to
$2,000,000 of Notes and Warrants, upon the approval of at least
 2/3 of the Board of Directors of the Company, which
 2/3 shall include a majority of the directors of
the Company who are not Purchasers or Affiliates of the Purchasers under this Purchase Agreement (the “Requisite Directors”). Subject to and upon the terms and conditions set forth in this Purchase Agreement, the purchase and sale
of Notes and Warrants in a Subsequent Tranche, if any, shall take place at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (or remotely via the exchange of documents and signatures), on the
date specified in the notice described below (which date shall be not less than ten (10) days nor more than thirty (30) days from the date such notice is deemed given pursuant to Section 8.04 hereof) or such other time and place as
the Company and the Purchasers agree upon orally or in writing (each such purchase and sale, if any, a “Subsequent Tranche Closing”). Each Subsequent Tranche Closing shall occur following notification from the Company to the
Purchasers (i) that the Requisite Directors have determined that it is advisable and in the best interests of the stockholders of the Company to conduct a Subsequent Tranche Closing, and (ii) indicating a date for such Subsequent Tranche
Closing. 
 2.03 Participation in Subsequent Tranches. In the event that the Company conducts a Subsequent
Tranche Closing and any Purchaser defaults (with respect to each such defaulting Purchaser, a “Subsequent Tranche Default”) on its obligation to purchase, in such Subsequent Tranche Closing, an amount of additional Notes and
Warrants at least equal to (i) the defaulting Purchaser’s allocation percentage of the Aggregate Bridge Amount, as set forth opposite the name of such Purchaser on Schedule A attached hereto under the caption “Allocation
Percentage,” multiplied by (ii) the aggregate amount of such Subsequent Tranche (each such defaulting Purchaser in any such Subsequent Tranche, a “Defaulting Purchaser”), effective immediately upon the consummation of the
Subsequent Tranche Closing, without action by the Company or such Defaulting Purchaser, (x) all Notes then outstanding under this Purchase Agreement that are held by such Defaulting Purchaser and each Affiliate thereof shall be

  

 4 

 
terminated pursuant to this Section 2.03 and Sections 6 and 7 of the Notes and the Company will be forever released from all of its obligations and liabilities under such Notes, including,
but not limited to, all obligations to pay the outstanding principal and any accrued interest on such Notes, and (y) all Warrants then outstanding under this Purchase Agreement that are held by such Defaulting Purchaser and each Affiliate
thereof shall be terminated pursuant to this Section 2.03 and Section 2 of the Warrants and the Company will be forever released from all of its obligations and liabilities under such Warrants. For purposes of determining the number of
Notes and Warrants purchased by a Purchaser at the Subsequent Tranche Closing, all Notes and Warrants purchased by Affiliates of such Purchaser at the Subsequent Tranche Closing shall be aggregated with the Notes and Warrants purchased by such
Purchaser (provided that no securities shall be attributed to more than one entity or person within any such group of affiliated entities or persons). For the avoidance of doubt, Purchasers may allocate and transfer their Notes and Warrants among
their Affiliates, in their sole discretion, and all Notes and Warrants being purchased by a Purchaser’s Affiliates shall be attributed to such Purchaser or group of such Purchaser’s Affiliates, as applicable, for purposes of determining
such Purchaser’s or such Purchaser’s Affiliates’ commitment to purchase its Allocation Percentage of the Aggregate Bridge Amount. 

2.04 Ranking; Allocation of Payments. The Notes shall rank equally without preference or priority of any kind over one another,
and all payments on account of principal and interest with respect to any of the Notes shall be applied ratably and proportionately among all of the Notes at the time outstanding in proportion, as nearly as practicable, to the respective unpaid
balances outstanding thereunder. Notwithstanding anything to the contrary herein, the indebtedness evidenced by the Notes shall be senior in right of payment to all of the Company’s other indebtedness, except the Senior Debt. 

2.05 Use of Proceeds. The proceeds from the sale of the Notes shall be used by the Company for working capital and general
corporate purposes, but shall not be used for the payment of principal on any outstanding Senior Debt, other than ordinary course monthly payments of principal and interest to Silicon Valley Bank under the Loan Agreement. 

ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

The Company hereby makes the following representations and warranties to the Purchasers as of each Closing, except as otherwise
indicated. 
 3.01 Incorporation, Good Standing and Qualification of the Company. The Company is a corporation duly
incorporated, validly existing and in good standing under the laws of its jurisdiction of organization. The Company has the requisite power and authority to own, lease and operate its properties and to carry on its business as now being conducted or
as proposed to be conducted. The Company is qualified as a foreign corporation and in good standing in the Commonwealth of Massachusetts. The conduct of the Company’s business and the ownership or lease of its property do not require it to
become qualified as a foreign corporation in any other jurisdiction where the failure to be so qualified would have a Material Adverse Effect. 
  

 5 

 3.02 Corporate Power and Authority; Authorization; Enforceability. All corporate
action on the part of the Company necessary for the authorization of this Purchase Agreement, the Notes, the Warrants and the performance of all obligations of the Company hereunder and thereunder has been taken or will be taken prior to such
Closing; provided, however, that the Company has not (i) amended its Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”), to create any New Stock nor (ii) reserved for issuance
any shares of the Company’s Common Stock or New Stock issuable pursuant to the terms of the Notes or the Warrants. This Purchase Agreement has been, and the Notes and Warrants will be, when executed and delivered at such Closing, duly executed
and delivered by the Company. This Purchase Agreement constitutes, and the Notes and Warrants when executed and delivered at such Closing, will constitute valid and binding obligations of the Company enforceable in accordance with their terms,
except as limited by (a) applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, and (b) general principles of equity that restrict the
availability of equitable remedies. 
 3.03 No Conflict. Neither the authorization, execution, delivery and performance
of this Purchase Agreement, the consummation of the transactions contemplated hereby, or the sale, issuance and delivery of the Notes, the Warrants or any of the shares of Capital Stock of the Company which may be issued pursuant to the terms of the
Notes and/or Warrants, as the case may be, will conflict with or result in a breach of or default under (or with due notice or lapse of time or both would result in a default under) the Company’s Certificate of Incorporation or by-laws, as
amended or any statute, law, rule, regulation, judgment, decree, writ, injunction, order or award of any arbitrator, court or governmental authority. 

3.04 Capitalization. The authorized Capital Stock of the Company consists of 60,000,000 shares of Common Stock, par value $0.001
per share, 4,912,963 of which shares are issued and outstanding, and 28,108,328 shares of preferred stock, 16,017,067 of which are designated as Series A Preferred Stock, par value $0.001 per share, 15,823,566 of which are issued and outstanding,
2,475,247 of which are designated as Series A-1 Preferred Stock, par value $0.001 per share, all of which are issued and outstanding, 2,000,000 of which are designated as Series B Preferred Stock, par value $0.001 per share, 1,138,716 of which
shares are issued and outstanding, 1,369,863 of which are designated as Series C Preferred Stock, par value $0.001 per share, all of which are issued and outstanding, and 6,246,151 of which are designated as Series D Preferred Stock, par value
$0.001 per share, 6,153,846 of which are issued and outstanding. All of the issued and outstanding shares of the Company’s Capital Stock have been duly authorized and validly issued and are fully paid and non-assessable and have been issued in
compliance with applicable Federal and state securities laws. The Company has reserved a total of 5,188,317 shares of its Common Stock for issuance pursuant to the Company’s 2001 Option and Incentive Plan, as amended, 4,945,853 of which are
subject to outstanding options as of the date hereof. The fully diluted as-converted outstanding capitalization of the Company prior to the First Closing is set forth on Schedule B. 

3.05 No Broker. The Company has no contract, arrangement or understanding with any broker, finder, agent, financial advisor or
other intermediary with respect to the transactions contemplated by this Purchase Agreement. 
  

 6 

 ARTICLE IV REPRESENTATION AND WARRANTIES OF THE PURCHASERS 

Each Purchaser hereby severally and not jointly represents and warrants to the Company with respect to such Purchaser as follows as of
each Closing, except as otherwise indicated. 
 4.01 Authorization. The execution, delivery and performance by each
Purchaser of this Purchase Agreement and the other Purchase Documents to which such Purchaser is a party have been duly authorized by all requisite corporate, partnership or other action on the part of such Purchaser. This Purchase Agreement and the
other Purchase Documents to which such Purchaser is a party have been duly executed and delivered by such Purchaser or on behalf of such Purchaser by a duly authorized representative of such Purchaser and constitute the valid and legally binding
obligations of such Purchaser enforceable against such Purchaser in accordance with their respective terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization and other laws affecting creditors’ rights
generally and by general equitable principles. 
 4.02 Investment Purpose; Restrictions. Each Purchaser is purchasing the
Notes and the Warrants for its own account, for investment and not with a view to the distribution thereof, nor with any present intention of distributing the same; and it is the intention of such Purchaser, if the Note is converted and/or Warrant
is exercised for equity securities of the Company, similarly to acquire any securities issued or issuable upon such conversion for such Purchaser’s own account, for investment and not with a view to the distribution thereof. Such Purchaser
understands and acknowledges that the issuance of the Notes and Warrants, and the securities issued or issuable upon conversion or exercise thereof have not been registered under the Securities Act, or applicable state securities laws and that such
securities therefore cannot be resold unless they are subsequently registered under the Securities Act and applicable state securities laws or unless an exemption from such registration is available. Each Purchaser further represents that it
understands and agrees that all certificates evidencing any of the Notes and Warrants, whether upon initial issuance or upon any permitted transfer thereof, shall bear a legend, prominently stamped or printed thereon, reading substantially as
follows: 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED BY ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE
SECURITIES ACT, OR (B) THE ISSUER SHALL HAVE RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER THAT AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT IS AVAILABLE, AND (2) THERE SHALL HAVE BEEN COMPLIANCE WITH ALL APPLICABLE
STATE SECURITIES OR “BLUE SKY” LAWS. 
 4.03 Information. Each Purchaser has been furnished with or has had
access to all information it has requested from the Company and has had an opportunity to review the books and records of the Company and to discuss with management of the Company its business and financial affairs and has generally such knowledge
and experience in business and financial 
  

 7 

 
matters and with respect to investments in securities of privately held development-stage companies so as to enable it to understand and evaluate the risks of such investment and form an
investment decision with respect thereto; provided, however, that the foregoing shall in no way affect, diminish, or derogate from the representations and warranties made by the Company hereunder or the right of such Purchaser to rely
thereon. 
 4.04 Accredited Investor. Each Purchaser is an “accredited investor” within the meaning set forth
in Rule 501 under the Securities Act, is capable of evaluating the merits and risks of the transactions contemplated hereunder, is able to bear the economic risks of its investment in the Notes and Warrants. 

4.05 Pre-Existing Relationship with Company. Each Purchaser is a current stockholder of the Company and was neither solicited to
purchase the Notes and Warrants in connection with or as a result of the filing by the Company of its IPO Registration Statement, nor became interested in investing in the Company on account of the Initial Public Offering. 

ARTICLE V CONDITIONS 

5.01 Conditions to Purchasers’ Obligations at the Closing. Purchasers’ obligations under Article II of this Purchase
Agreement are subject to the satisfaction, at or prior to the applicable Closing, of the following conditions: 
 (a)
Representations and Warranties True; Performance of Obligations. The representations and warranties made by the Company in Article III hereof shall be true and correct in all material respects as of each Closing; 

(b) Legal Investment. On each Closing, the sale and issuance of the Notes and the Warrants shall be legally permitted by all laws
and regulations to which Purchasers and the Company are subject; 
 (c) Consents, Permits, and Waivers. The Company shall
have obtained any and all consents, permits and waivers necessary or appropriate for consummation of the transactions contemplated by this Purchase Agreement (except for such as may be properly obtained subsequent to the First Closing); and

 (d) Delivery of the Notes and Warrants. The Company shall have delivered the appropriate Notes and Warrants to each
Purchaser. 
 5.02 Conditions to Obligations of the Company. The Company’s obligation to issue and sell the Notes
and the Warrants is subject to the satisfaction, at or prior to the applicable Closing, of the following conditions: 
 (a)
Representations and Warranties True. The representations and warranties in Article IV made by the Purchasers shall be true and correct as of each Closing; 

(b) Legal Investment. On each Closing, the sale and issuance of the Notes and the Warrants shall be legally permitted by all laws
and regulations to which Purchasers and the Company are subject; 
  

 8 

 (c) Consents, Permits, and Waivers. The Company shall have obtained any and all
consents, permits and waivers necessary or appropriate for consummation of the transactions contemplated by this Purchase Agreement (except for such as may be properly obtained subsequent to the First Closing); and 

(d) Purchase Price Delivery. The Company shall have received from each Purchaser in immediately available funds the principal
amount of such Purchaser’s Note. 
 ARTICLE VI AFFIRMATIVE COVENANTS OF THE COMPANY 

For so long any Notes or Warrants are outstanding, the Company agrees to the following: 

6.01 Payment of Notes. The Company will punctually pay or cause to be paid the principal of and interest on the Notes at the times
and places and in the manner specified in the Notes. 
 6.02 Reservation of Shares of Capital Stock. The Company agrees
to take any and all corporate action, prior to the issuance of any shares of capital stock upon conversion of the Notes, as is necessary or desirable to authorize, reserve and issue the New Stock or Common Stock and any shares of the Company’s
Capital Stock issuable upon conversion of the New Stock promptly upon a determination of the terms of such securities, or any shares of the Company’s Capital Stock into which the Notes may be converted or the Warrants may be exercised.

 6.03 Further Assurances. The Company shall execute any and all further documents, and take all further action which
any Purchaser may reasonably request in order to effectuate the transactions contemplated by the Purchase Documents. 

ARTICLE VII EVENTS OF DEFAULT 

7.01 Events of Default. If any of the following events (each, an “Event of Default”) shall occur and be
continuing: 
 (a) default in the payment when due of any principal or interest under the Notes, and such nonpayment shall
continue uncured for a period of five business days after written notice by the Purchaser thereof; 
 (b)
any material breach in the performance or observance of any of the representations or warranties by the Company contained in this Purchase Agreement, and such breach continues for a period of thirty (30) days after written notice of such
failure requiring the Company to remedy the same has been given to the Company by the Purchasers holding Notes with at least 66 2/
3% of the aggregate principal amounts then outstanding under all of the Notes; 

(c) the institution against the Company or any endorser or guarantor of the Notes of any proceedings under the United States Bankruptcy
Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, which proceeding is not dismissed within thirty (30) days of filing; or the

  

 9 

 
institution by the Company or any endorser or guarantor of the Notes of any proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization,
receivership, insolvency or other similar law affecting the rights of creditors generally or the making by the Company or any endorser or guarantor of the Notes of a composition or an assignment or trust mortgage for the benefit of creditors; or

 (d) the Company’s cessation wholly to carry on its business (other than as a result of the merger or
consolidation of the Company with another entity), without the prior written consent of the Purchasers holding Notes with at least
66 2/3% of the aggregate principal amounts then
outstanding under all of the Notes (such consent not to be unreasonably withheld); 
 then, and in any such event,
each Purchaser may, by notice to the Company, declare the entire unpaid principal amount of such Purchaser’s Note, all interest accrued and unpaid thereon and all other amounts payable under such Note to be forthwith due and payable, whereupon
such Note, all such accrued interest and all such amounts shall become and be forthwith due and payable; provided that, in the case of any Event of Default pursuant to either of clauses (c) and (d) above, all interest accrued and unpaid
thereon and all other amounts payable under such Note to be forthwith due and payable without notice or demand. 
 ARTICLE
VIII MISCELLANEOUS 
 8.01 Amendments and Waivers. This Purchase Agreement and the Notes may
be amended or modified, and any term or provision hereof or thereof may be waived (either generally or in a particular instance and either retroactively or prospectively) upon the written consent of the Company and the Purchasers holding Notes with
at least 66 2/3% of the aggregate principal amounts
then outstanding under all of the Notes. The Warrants may be amended or modified, and any term or provision thereof may be waived (either generally or in a particular instance and either retroactively or prospectively) upon the written consent of
the Company and the Purchasers holding Warrants with at least
66 2/3% of the aggregate shares issuable under all
of the Warrants then outstanding. However, in no event shall the specific terms and provisions of a Note or Warrant be amended, modified or waived in a manner that is different from any other Note or Warrant without the specific consent of the
holder of such Note or Warrant and the Company. Any amendment or modification of this Purchase Agreement, the Notes or Warrants, or waiver of any term or provision of this Purchase Agreement, the Notes or Warrants effected in accordance with this
Purchase Agreement, the Notes or Warrants, as applicable, shall be binding upon each Purchaser under this Purchase Agreement. 

8.02 No Shareholder Rights. Nothing contained in this Purchase Agreement or the Notes and the Warrants shall be construed as
conferring upon any Purchaser the right to vote or to consent or to receive notice as a shareholder in respect of meetings of shareholders for the election of directors of the Company or any other matters or any rights whatsoever as a shareholder of
the Company and (ii) no dividends shall be payable or accrued in respect of the Notes and the Warrants or the shares obtainable thereunder, in both cases of (i) and (ii) until, and only to the extent that, the Notes and the Warrants
shall have been duly converted into and/or exercised for shares. 
  

 10 

 8.03 Successors and Assigns. This Purchase Agreement may not be assigned, conveyed or
transferred without the prior written consent of the Company; provided, however, a Purchaser that is partnership, corporation, trust, joint venture, unincorporated organization or other entity may transfer this Purchase Agreement to an
Affiliate without the prior written consent of the Company. Subject to the foregoing, the rights and obligations of the Company and each Purchaser under this Purchase Agreement shall be binding upon and benefit their respective permitted successors,
assigns, heirs, administrators and transferees. The terms and provisions of this Purchase Agreement are for the sole benefit of the parties hereto and their respective permitted successors and assigns, and are not intended to confer any third-party
benefit on any other person. 
 8.04 Notices. All notices, requests and demands to or upon the respective parties hereto
to be effective shall be in writing, and, unless otherwise expressly provided herein, shall be deemed to have been duly given or made when delivered by hand, or, in the case of telecopy notice, when received, or, in the case of a nationally
recognized courier service, one business day after delivery to such courier service, addressed as follows in the case of the Company and the Purchasers or to such other address as may be hereafter notified by the respective parties hereto and any
future holders of the Notes: 
  

			
	Company:	  	 BG Medicine, Inc.
 610 N
Lincoln Street
 Waltham, Massachusetts 02451

Attn: President

		
	With a copy to:	  	 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center
 Boston, Massachusetts 02111

 Attn: William T. Whelan, Esq.

		
	Purchasers:	  	To the addresses set forth on Schedule A

8.05 Waiver; Cumulative Remedies. No failure to exercise and no delay in exercising, on the part of any Purchaser, any right,
remedy, power or privilege hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right,
remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law. 

8.06 Payment of Fees, Expenses. Each of the parties hereto shall bear its own costs and expenses in connection with the
transactions contemplated hereunder, except the Company shall pay at the First Closing the reasonable fees and expenses of outside legal counsel, if any, up to an aggregate of
$            , incurred by the Purchasers in connection with the transactions contemplated hereunder. 

8.07 Counterparts. This Purchase Agreement may be executed by one or more of the parties to this Purchase Agreement on any number
of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. 
  

 11 

 8.08 Severability. Any provision of this Purchase Agreement which is prohibited or
unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any
jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 
 8.09 Integration.
This Purchase Agreement and the other Purchase Documents represent the agreement of the Company and the Purchasers with respect to the subject matter hereof, and there are no promises, undertakings, representations or warranties by the Purchasers
relative to the subject matter hereof not expressly set forth or referred to herein or in the other Purchase Documents. 

8.10 Governing Law. This Purchase Agreement shall be construed and enforced in accordance with and governed by the State of
Delaware, without giving effect to the conflicts of law principles thereof. 
 8.11 Jurisdiction and Service of Process.
Any legal action or proceeding with respect to this Purchase Agreement shall be brought in the courts of the State of Delaware or of the United States of America for the District of Delaware. By execution and delivery of this Purchase Agreement,
each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the jurisdiction of the aforesaid courts. Each of the parties hereto irrevocably consents to the service of process of any of the
aforementioned courts in any such action or proceeding by the mailing of copies thereof by certified mail, postage prepaid, to the party at its address set forth in Section 8.04 hereof. 

8.12 Right of First Refusal. Each Purchaser who has a right of first offer, preemptive or other similar right to purchase
securities in connection with the offering of securities pursuant to this Purchase Agreement, whether arising under any agreement with the Company or any other legal principle, hereby agrees that the purchase of securities by such Purchaser
hereunder is in full satisfaction of any and all such rights. The terms of any such agreement governing any such right of first offer, preemptive or other similar rights are hereby expressly waived by such Purchaser. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 
  

 12 

 IN WITNESS WHEREOF, the parties hereto have caused this Purchase Agreement to be duly
executed and delivered by their proper and duly authorized officers as of the day and year first above written. 
  

			
	BG Medicine, Inc.
		
	By:	 	 /s/ Pieter Muntendam

		 	Pieter Muntendam, M.D., President

[ADDITIONAL COUNTERPART SIGNATURE PAGES BEGIN ON NEXT PAGE] 

 

 13 

 COUNTERPART SIGNATURE PAGE 

TO SECURITIES PURCHASE AGREEMENT 

By execution of this Signature Page, the undersigned Purchaser does hereby become a party to and agrees to be bound by the provisions of the Securities
Purchase Agreement, to which this Signature Page is appended, as a “Purchaser” party, a counterpart of which has been furnished to the undersigned, and the undersigned hereby authorizes the Company to append this Signature Page to a
counterpart of the Securities Purchase Agreement as evidence thereof. This Counterpart Signature Page shall take effect and shall become part of the Securities Purchase Agreement immediately upon execution. 

 

			
	FLAGSHIP VENTURES:
	
	NEWCOGEN GROUP LLC;
	NEWCOGEN EQUITY INVESTORS LLC;
	NEWCOGEN PE LLC;
	NEWCOGEN ÉLAN LLC;
	ST NEWCOGEN LLC;
	NEWCOGEN LONG REIGN HOLDING LLC
	
	Each by its Manager NewcoGen Group Inc.
		
	By:	 	 /s/ Noubar B. Afeyan

		 	Noubar B. Afeyan
		 	President
	
	Applied Genomic Technology Capital Fund, L.P.;
	AGTC Advisors Fund, L.P.
	
	Each by its General Partner, AGTC Partners, L.P.
	By its General Partner, NewcoGen Group Inc.
		
	By:	 	 /s/ Noubar B. Afeyan

		 	Noubar B. Afeyan
		 	President

  

 COUNTERPART SIGNATURE PAGE 

TO SECURITIES PURCHASE AGREEMENT 

By execution of this Signature Page, the undersigned Purchaser does hereby become a party to and agrees to be bound by the provisions of the Securities
Purchase Agreement, to which this Signature Page is appended, as a “Purchaser” party, a counterpart of which has been furnished to the undersigned, and the undersigned hereby authorizes the Company to append this Signature Page to a
counterpart of the Securities Purchase Agreement as evidence thereof. This Counterpart Signature Page shall take effect and shall become part of the Securities Purchase Agreement immediately upon execution. 

 

					
	GILDE EUROPE FOOD & AGRIBUSINESS FUND B.V.
			
	By:	 	 /s/ P.H. van der Meer
	 	 /s/ Marc Perret

	Name:	 	P.H. van der Meer	 	Marc Perret
	Title:	 	Partner	 	Director

  

 COUNTERPART SIGNATURE PAGE 

TO SECURITIES PURCHASE AGREEMENT 

By execution of this Signature Page, the undersigned Purchaser does hereby become a party to and agrees to be bound by the provisions of the Securities
Purchase Agreement, to which this Signature Page is appended, as a “Purchaser” party, a counterpart of which has been furnished to the undersigned, and the undersigned hereby authorizes the Company to append this Signature Page to a
counterpart of the Securities Purchase Agreement as evidence thereof. This Counterpart Signature Page shall take effect and shall become part of the Securities Purchase Agreement immediately upon execution. 

 

			
	By:	 	 /s/ Stelios Papadopoulos

	Name:	 	Stelios Papadopoulos

 COUNTERPART SIGNATURE PAGE 

TO SECURITIES PURCHASE AGREEMENT 

By execution of this Signature Page, the undersigned Purchaser does hereby become a party to and agrees to be bound by the provisions of the Securities
Purchase Agreement, to which this Signature Page is appended, as a “Purchaser” party, a counterpart of which has been furnished to the undersigned, and the undersigned hereby authorizes the Company to append this Signature Page to a
counterpart of the Securities Purchase Agreement as evidence thereof. This Counterpart Signature Page shall take effect and shall become part of the Securities Purchase Agreement immediately upon execution. 

 

			
	HUMANA INC.
		
	By:	 	 /s/ Ralph Wilson

	Name:	 	Ralph Wilson
	Title:	 	Vice President and Associate General Counsel

  

 COUNTERPART SIGNATURE PAGE 

TO SECURITIES PURCHASE AGREEMENT 

By execution of this Signature Page, the undersigned Purchaser does hereby become a party to and agrees to be bound by the provisions of the Securities
Purchase Agreement, to which this Signature Page is appended, as a “Purchaser” party, a counterpart of which has been furnished to the undersigned, and the undersigned hereby authorizes the Company to append this Signature Page to a
counterpart of the Securities Purchase Agreement as evidence thereof. This Counterpart Signature Page shall take effect and shall become part of the Securities Purchase Agreement immediately upon execution. 

 

			
	SMALLCAP WORLD FUND, INC.
	By Capital Research and Management Company,
	its investment adviser
	(shares in name of Clipperbay & Co., HG 22)
		
	By:	 	 /s/ Michael J. Downer

	Name:	 	Michael J. Downer
	Title:	 	Senior Vice President and Secretary

 COUNTERPART SIGNATURE PAGE 

TO SECURITIES PURCHASE AGREEMENT 

By execution of this Signature Page, the undersigned Purchaser does hereby become a party to and agrees to be bound by the provisions of the Securities
Purchase Agreement, to which this Signature Page is appended, as a “Purchaser” party, a counterpart of which has been furnished to the undersigned, and the undersigned hereby authorizes the Company to append this Signature Page to a
counterpart of the Securities Purchase Agreement as evidence thereof. This Counterpart Signature Page shall take effect and shall become part of the Securities Purchase Agreement immediately upon execution. 

 

			
	LEGG MASON SPECIAL INVESTMENT TRUST, INC.
	(shares in name of Tidalwave & Co.)
		
	By:	 	 /s/ Richard M. Wachterman

	Name:	 	Richard M. Wachterman
	Title:	 	Assistant Secretary

 COUNTERPART SIGNATURE PAGE 

TO SECURITIES PURCHASE AGREEMENT 

By execution of this Signature Page, the undersigned Purchaser does hereby become a party to and agrees to be bound by the provisions of the Securities
Purchase Agreement, to which this Signature Page is appended, as a “Purchaser” party, a counterpart of which has been furnished to the undersigned, and the undersigned hereby authorizes the Company to append this Signature Page to a
counterpart of the Securities Purchase Agreement as evidence thereof. This Counterpart Signature Page shall take effect and shall become part of the Securities Purchase Agreement immediately upon execution. 

 

			
	GENERAL ELECTRIC PENSION TRUST
	By GE Asset Management Incorporated,
	its Investment Manager
		
	By:	 	 /s/ Patrick J. McNeela

	Name:	 	Patrick J. McNeela
	Title:	 	 Senior Managing Director &

Chief Investment Officer

 COUNTERPART SIGNATURE PAGE 

TO SECURITIES PURCHASE AGREEMENT 

By execution of this Signature Page, the undersigned Purchaser does hereby become a party to and agrees to be bound by the provisions of the Securities
Purchase Agreement, to which this Signature Page is appended, as a “Purchaser” party, a counterpart of which has been furnished to the undersigned, and the undersigned hereby authorizes the Company to append this Signature Page to a
counterpart of the Securities Purchase Agreement as evidence thereof. This Counterpart Signature Page shall take effect and shall become part of the Securities Purchase Agreement immediately upon execution. 

 

							
	[Signature Block for Individuals]	 		 	[Signature Block for Entities]
			
	  
	 		 	  

	Signature	 		 	Name of Entity
				
	  
	 		 	By:	 	  

	Printed Name	 		 	Name:	 	  

		 		 	Title:	 	  

 SCHEDULE A 

List of Purchasers 
  

											
	 Purchasers
	  	Allocation
Percentage	 	 	Issuance
Date of Securities
	  	Principal
Amount of 
Note	  	Number of
Warrant 
Shares
	 Applied Genomic Technology Capital Fund, L.P.

c/o Flagship Ventures
	  	0.01	% 	 	1) March 30, 2010	  	$	100	  	11
					
	 AGTC Advisors Fund, L.P.

c/o Flagship Ventures
	  	0.001	% 	 	1) March 30, 2010	  	$	10	  	1
					
	 NewcoGen Group LLC

c/o Flagship Ventures
	  	12.43	% 	 	1) March 30, 2010	  	$	246,724	  	28,468
					
	 NewcoGen Equity Investors LLC

c/o Flagship Ventures
	  	8.80	% 	 	1) March 30, 2010	  	$	175,984	  	20,305
					
	 NewcoGen-Long Reign Holding LLC

c/o Flagship Ventures
	  	1.25	% 	 	1) March 30, 2010	  	$	24,976	  	2,881
					
	 NewcoGen-PE LLC

c/o Flagship Ventures
	  	5.06	% 	 	1) March 30, 2010	  	$	101,133	  	11,669

											
	 Purchasers
	  	Allocation
Percentage	 	 	Issuance
Date of Securities
	  	Principal
Amount of 
Note	  	Number of
Warrant 
Shares
	 NewcoGen Élan LLC

c/o Flagship Ventures
	  	4.64	% 	 	1) March 30, 2010	  	$	92,769	  	10,704
					
	 ST NewcoGen LLC

c/o Flagship Ventures
	  	1.25	% 	 	1) March 30, 2010	  	$	24,904	  	2,873
					
	FLAGSHIP SUBTOTAL:	  	33.33	% 	 	1) March 30, 2010	  	$	666,600	  	76,912
					
	 GILDE EUROPE FOOD & AGRIBUSINESS FUND B.V.
	  	16.67	% 	 	1) April 1, 2010	  	$	333,400	  	38,469
					
	 Stelios Papadopoulos
	  	4.17	% 	 	1) March 30, 2010	  	$	83,400	  	9,623
					
	 Humana Inc.
	  	8.33	% 	 	1) March 30, 2010	  	$	166,600	  	19,223
					
	 SMALLCAP World Fund, Inc.

(nominee name: Clipperbay & Co. HG 22)

c/o Capital Research and Management Company
	  	12.5	% 	 	1) March 30, 2010	  	$	250,000	  	28,846

											
	 Purchasers
	  	Allocation
Percentage	 	 	Issuance
Date of Securities
	  	Principal
Amount of 
Note	  	Number of
Warrant 
Shares
	 Legg Mason Special Investment Trust, Inc.

(shares in name of Tidalwave & Co.)

c/o Legg Mason Capital Management
	  	12.5	% 	 	1) March 30, 2010	  	$	250,000	  	28,846
					
	 General Electric Pension Trust

c/o GE Asset Management Incorporated
	  	12.5	% 	 	1) March 30, 2010	  	$	250,000	  	28,846
					
	 TOTAL FIRST CLOSING:
	  			 		  	$	2,000,000	  	230,765

 EXHIBIT A 

FORM OF CONVERTIBLE PROMISSORY NOTE 

 EXHIBIT B 

FORM OF COMMON STOCK WARRANT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]